All In Biotech

NDA 021318 · Lilly

Forteo

Teriparatide · Subcutaneous · Parathyroid Hormone Analog

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Nov 26, 2002

Approved uses

3

Original approval plus efficacy supplements

Registered trials

155

34 Phase 3, 5 recruiting

FAERS reports

112,496

41,897 serious, 5,314 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 3, 2026.

FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. FORTEO is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )

Mechanism: Endogenous 84-amino acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. The biological actions of PTH and teriparatide are mediated through binding to specific high-affinity cell-surface receptors. Teriparatide and the 34 N-terminal amino acids of PTH bind to these receptors with the same affinity and have the same physiological actions on bone and kidney. Teriparatide is not...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • FORTEO · TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
  • FORTEO · TERIPARATIDE 0.75MG/3ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Teriparatide" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea9,026
  • arthralgia8,725
  • pain in extremity8,375
  • dizziness8,337
  • fall7,933
  • pain7,575
  • fatigue7,225
  • back pain5,948
  • muscle spasms5,753
  • malaise5,689
  • headache5,528
  • asthenia5,454

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046,414
20054,792
20062,193
20072,193
20082,133
20093,068
20103,799
20115,405
20126,250
20132,648
20141,297
201544,975
20162,140
20174,040
20184,898
20194,011
20201,957
20211,813
20221,581
20231,757
20241,839
20252,090
20261,203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Forteo (Teriparatide)

2024 spending

$266M

Beneficiaries

11,433

67,653 claims

Per beneficiary

$23,297

$1,571.07 per unit

View as table
YearSpending
2020$457,345,880
2021$371,324,574
2022$368,538,667
2023$425,012,975
2024$266,352,818

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 490 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.